Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome
By: Steve C. Han, Linn Katus and Steven Frucht
References
- 1de Souza A. Movement disorders and the osmotic demyelination syndrome. Parkinsonism & Related Disorders. 2013; 19(8): 709–16. DOI: 10.1016/j.parkreldis.2013.04.005
- 2Alleman AM. Osmotic demyelination syndrome: Central pontine myelinolysis and extrapontine myelinolysis. Semin Ultrasound CT MR. 2014; 35(2): 153–9. DOI: 10.1053/j.sult.2013.09.009
- 3Graff-Radford J, Kaufmann JE, Mandrekar TJ, Rabinstein JN, Rabinstein AA. Clinical and Radiologic Correlations of Central Pontine Myelinolysis Syndrome. Mayo Clinic Proceedings. 2011; 86(11): 1063–7. DOI: 10.4065/mcp.2011.0239
- 4King JD, Rosner MH. Osmotic demyelination syndrome. Am J Med Sci. 2010; 339(6): 561–7. DOI: 10.1097/MAJ.0b013e3181d3cd78
- 5Watts RL. The role of dopamine agonists in early Parkinson’s disease. Neurology. 1997; 49: S34–S8. DOI: 10.1212/WNL.49.1_Suppl_1.S34
- 6Hisahara S, Shimohama S. Dopamine receptors and Parkinson’s disease. Int J Med Chem; 2011. DOI: 10.1155/2011/403039
- 7Radad KG, Gille G, Rausch, W. Short review on dopamine agonists: Insight into clinical and research studies relevant to Parkinson’s disease. Pharmacological Reports. 2005; 57: 701–12.
- 8Gujjar, AA-M, Al-Mamari A, Jacob, PC, Jain R, Balkhair A, Al-Asmi A. Extrapontine myelinolysis as presenting manifestation of adrenal failure: A case report. Journal of the Neurological Sciences. 2010; 290: 169–71. DOI: 10.1016/j.jns.2009.11.012
- 9Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J. Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson’s Disease Patients. Journal of Parkinson’s Disease. 2015; 5: 165–74. DOI: 10.3233/JPD-140456
- 10Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated. TRENDS in Neurosciences. 2003; 26(4): 215–21. DOI: 10.1016/S0166-2236(03)00038-9
- 11Wood M, Dubois V, Scheller D, Gillard M. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. British Journal of Pharmacology. 2015; 172: 1124–35. DOI: 10.1111/bph.12988
- 12Abdul Halim S, Mohd Amin NA. Treatment response in osmotic demyelination syndrome presenting as severe parkinsonism, ptosis and gaze palsy. BMJ Case Rep. 2018; 2018. DOI: 10.1136/bcr-2018-225751
- 13Rizvi I, Ahmad M, Gupta A, Zaidi N. Isolated extra pontine myelinolysis presenting as acute onset parkinsonism. BMJ Case Rep. 2012; 2012. DOI: 10.1136/bcr-2012-007140
- 14Imam YZ, Saqqur M, Alhail H, Deleu D. Extrapontine myelinolysis-induced parkinsonism in a patient with adrenal crisis. Case Rep Neurol Med. 2012; 2012:
327058 . DOI: 10.1155/2012/327058 - 15Kwon DY, Seo WK, Park MH, Kang YS, Koh SB, Cha DR, et al. Rapidly deteriorating parkinsonism and dysautonomia in patient with central pontine and extrapontine myelinolysis. Clin Neurol Neurosurg. 2011; 113(6): 513–4. DOI: 10.1016/j.clineuro.2011.02.002
- 16Toft M, Dietrichs E. Levodopa-responsive parkinsonism in probable extrapontine myelinolysis of the mesencephalon. Mov Disord. 2011; 26(12): 2180–1. DOI: 10.1002/mds.23876
- 17Post B, van Gool WA, Tijssen MA. Transient Parkinsonism in isolated extrapontine myelinolysis. Neurol Sci. 2009; 30(4): 325–8. DOI: 10.1007/s10072-009-0088-9
- 18Sajith J, Ditchfield A, Katifi HA. Extrapontine myelinolysis presenting as acute parkinsonism. BMC Neurol. 2006; 6: 33. DOI: 10.1186/1471-2377-6-33
- 19Seah ABH, Chan LL, Wong MC, Tan EK. Evolving spectrum of movement disorders in extrapontine and central pontine myelinolysis. Parkinsonism & Related Disorders. 2002; 9: 117–9. DOI: 10.1016/S1353-8020(02)00002-0
- 20Kim JS, Lee KS, Han SR, Chung YA. Decreased Striatal Dopamine Transporter Binding in a Patietn with Extrapontine Myelinolysis. Movement Disorders. 2003; 18(3): 342–5. DOI: 10.1002/mds.10331
- 21Nagamitsu S, Matsuishi T, Yamashita Y, Yamada S, Kato H. Extrapontine myelinolysis with parkinsonism after rapid correction of hyponatremia: high cerebrospinal fluid level of homovanillic acid and successful dopaminergic treatment. Journal of Neural Transmission. 1999; 106: 949–53. DOI: 10.1007/s007020050215
- 22Schwarz AS, Aichinger-Steiner MM, Funk G, Schnider P, Brainin M. Parkinsonism and dystonia in central pointine and extrapontine myelinolysis. Journal of Neurology, Neurosurgery & Psychiatry. 1998; 65: 119–21. DOI: 10.1136/jnnp.65.1.119
- 23Maraganore DM, Folger WN, Swanson JW, Ahlskog JE. Movement Disorders as Sequelae of Central Pontine Myelinolysis: Report of Three Cases. Movement Disorders. 1992; 7(2): 142–8. DOI: 10.1002/mds.870070208
- 24Tison FX, Ferre X, Julien J. Delayed Onset Movement Disorders as a Complication of Central Pontine Myelinolysis. Movement Disorders. 1991; 6(2): 171–3. DOI: 10.1002/mds.870060215
DOI: https://doi.org/10.5334/tohm.66 | Journal eISSN: 2160-8288
Language: English
Submitted on: Jan 2, 2020
Accepted on: Apr 15, 2020
Published on: Jun 16, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2020 Steve C. Han, Linn Katus, Steven Frucht, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.